DRW Securities LLC Makes New $1.59 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

DRW Securities LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 4,757 shares of the medical research company's stock, valued at approximately $1,592,000.

Other hedge funds have also bought and sold shares of the company. UMB Bank n.a. lifted its holdings in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after acquiring an additional 45 shares during the period. Capital Advisors Ltd. LLC increased its position in Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after buying an additional 62 shares during the last quarter. Gladius Capital Management LP purchased a new stake in Bio-Rad Laboratories in the third quarter worth $32,000. Headlands Technologies LLC purchased a new stake in Bio-Rad Laboratories in the second quarter worth $51,000. Finally, Quarry LP purchased a new stake in Bio-Rad Laboratories in the second quarter worth $59,000. 65.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Royal Bank of Canada raised their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target for the company. StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Finally, Citigroup boosted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Price Performance

BIO stock traded up $2.15 during mid-day trading on Tuesday, hitting $338.24. 167,708 shares of the stock were exchanged, compared to its average volume of 245,949. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The business has a fifty day moving average price of $340.63 and a 200 day moving average price of $316.68. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The stock has a market capitalization of $9.47 billion, a price-to-earnings ratio of -12.36 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. During the same quarter in the previous year, the company posted $2.33 earnings per share. The company's revenue was up 2.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Insider Activity

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares of the company's stock, valued at $2,494,016.46. This represents a 28.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP James Barry sold 623 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company's stock, valued at $48,582.03. The trade was a 80.91 % decrease in their position. The disclosure for this sale can be found here. 17.50% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.